A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma

Inclusion Criteria Patients must have: * Serum HIV antibody positive by ELISA. * KS documented by biopsy (repeat biopsy is not required for entry if KS has been previously confirmed histologically and the histopathology report has been reviewed). * A minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions, each of which has been present for at least 30 days or has a longest dimension of at least 10mm, and has not received prior local or topical therapy within 60 days of study entry. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Concurrent, serious, uncontrolled infection including, but not limited to: * Mycobacterium avium intracellulare or other mycobacterium infection; Pneumocystis carinii pneumonia; CMV retinitis or colitis; Toxoplasma brain abscess; Cryptococcal meningitis. * Serious intercurrent illness or infection that would interfere with the ability of the patient to carry out the treatment program. * Known allergy or sensitivity to retinoid class drugs. Concurrent Medication: Excluded: * Local or topical therapy such as, but not limited to, Vitamin A, tretinoin (all-trans-retinoic acid), other retinoid class drugs, or intralesional (injection) therapy to any KS indicator lesion. * Systemic anticancer chemotherapy, systemic anticancer hormonal therapy, and/or systemic anticancer immunotherapy. * Systemic use of retinoid class drugs, beta-carotene compounds, or Vitamin A in doses greater than 15,000 IU (5,000 mcg) per day (equivalent to approximately 3 times the RDA) for any indication. * Human chorionic gonadotropin. Concurrent Treatment: Excluded: Radiotherapy, cryotherapy, photodynamic therapy, and/or laser therapy for any KS indicator lesion. Prior Medication: Excluded: * Systemic treatment of KS within 30 days of study entry. * Systemic treatment with either Vitamin A in doses greater than 15,000 IU (5,000 mcg) per day (equivalent to approximately 3 times the RDA) or other retinoid class drugs for any indication within 30 days of study entry. * Previous local or topical therapy of any KS indicator lesion such as, but not limited to, Vitamin A, tretinoin (all-trans-retinoic acid), other retinoid class drugs, or intralesional (injection) therapy within 60 days of study entry. Prior Treatment: Excluded: * Radiotherapy, cryotherapy, photodynamic therapy and/or laser therapy within 60 days of study entry.